Company intelligence / Profile preview

Critical Biologics Corporation

Cambridge, Massachusetts, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Critical Biologics is developing a theranostic platform to identify and treat patients at high risk for life-threatening complications due to hypogelsolinemia. Their lead product is recombinant human plasma gelsolin (rhu-pGSN), which has shown efficacy in animal models for averting disease progression when administered after tissue injury. The company recently secured $7 million in Series A financing to advance this program. No published clinical results are available.

Therapeutic areas: Critical Care
Modalities: Recombinant proteins (specifically recombinant human plasma gelsolin, rhu-pGSN)
Industry: Biotech

Drug pipeline

1 asset

rhu-pGSN

Pre-clinical

Indications: Critical care complications, Trauma, Burns, Sepsis

Partnerships

Morningside Ventures (investor and strategic partner)

Beyond the preview

Go deeper on Critical Biologics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Critical Biologics Corporation.

Explore the full profile